|
[1]WALLACE MC, FRIEDMAN SL, MANN DA. Emerging and disease-specific mechanisms of hepatic stellate cell activation[J]. Semin Liver Dis, 2015, 35 (2) :107-118.
|
|
[2]WANLESS IR, NAKASHIMA E, SHERMAN M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.
|
|
[3]LOK AS. Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (4) :199-200.
|
|
[4]LIU CH, LIU P, HU YY, et al. Advances in clinical and basic research on anti-hepatic fibrosis of traditional Chinese medicine[J]. World Sci Technol Modern Tradit chin Med, 2007, 9 (2) :112-119. (in Chinese) 刘成海, 刘平, 胡义扬, 等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术-中医药现代化, 2007, 9 (2) :112-119.
|
|
[5]YANG SX, SUN SL, ZHANG XW. Qianshi collection (episode4, experience and salary transfer of famous Chinese medicine doctors) [M]. Xi'an:Shaanxi Science and Technology Press, 2003:84-87. (in Chinese) 杨世兴, 孙塑伦, 张学文.碥石集 (第4集, 著名中医学家经验传薪) [M].西安:陕西科学技术出版社, 2003:84-87.
|
|
[6]BEI RP. Jiang Chunhua's experience in the treatment of liver cirrhosis[J]. J Tradit Chin Med, 1983, 2:12-14. (in Chinese) 贝润浦.姜春华治疗肝硬化的经验[J].中医杂志, 1983, 2:12-14.
|
|
[7]LIU C, HU Y, XU L, et al. Effect of Fuzheng Huayu formula and its actions against liver fibrosis[J]. Chin Med, 2009, 4:12.
|
|
[8]ZHOU T, LIU CH, CHEN Y, et al. Guiding role of qi-blood theory in treatment of liver fibrosis due to chronic liver diseases[J]. Acta Univ Tradit Med Sin Pharmacol Shanghai, 2007, 21 (2) :34-36. (in Chinese) 周滔, 刘成海, 陈园, 等.气血理论在慢性肝病肝纤维化治疗中的指导作用[J].上海中医药大学学报, 2007, 21 (2) :34-36.
|
|
[9]Chinese Association of lntegrative Medicine, Liver Disease Committee. Guideline for the diagnosis and treatment of liver fibrosis with integrative medicine[J]. Chin J Integr Tradit West Med Liver Dis, 2006, 16 (5) :316-320. (in Chinese) 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中西医结合肝病杂志, 2006, 16 (5) :316-320.
|
|
[10]LIU P, HU YY, LIU C, et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B[J]. World J Gastroenterol, 2005, 11 (19) :2892-2899.
|
|
[11]HASSANEIN T, BOX TD, TONG MJ, et al. A phase II, randomized, placebo-controlled, double-blind, multicenter study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis[J]. Hepatol Int, 2014, 8:s308-s309.
|
|
[12]ZHOU GD, LI WS, ZHAO JM, et al. Clinical pathological study on the mechanism of effect of Fufangbiejiaruanganpian in treatment of liver fibrosis[J]. Med J Chin PLA, 2004, 29 (7) :563-564. (in Chinese) 周光德, 李文淑, 赵景民, 等.复方鳖甲软肝片抗肝纤维化机制的临床病理研究[J].解放军医学杂志, 2004, 29 (7) :563-564.
|
|
[13]YIN SS, WANG BE, WANG TL, et al. The effect of Cpd 861on chronic hepatitis B related fibrosis and early cirrhosis:a randomized, double blind, placebo controlled clinical trial[J].Chin J Hepatol, 2004, 12 (8) :467-470. (in Chinese) 尹珊珊, 王宝恩, 王泰龄, 等.复方861治疗慢性乙型肝炎肝纤维化与早期肝硬化的临床研究[J].中华肝脏病杂志, 2004, 12 (8) :467-470.
|
|
[14]CAI ST. Clinical study on early liver fibrosis of chronic hepatitis B treated with Auluohuaxianwan[D]. Fuzhou:Fujian University of Traditional Chinese Medicine, 2017. (in Chinese) 蔡少桐.安络化纤丸阻断慢性乙型肝炎早期肝纤维化的临床研究[D].福州:福建中医药大学, 2017.
|
|
[15]TANG LR, GUO T, TAO YY, et al. A systematic review of combinative effects of Fuzheng Huayu capsule with nucleotide analogues on liver fibrosis due to chronic hepatitis B[J]. Chin J Integr Tradit West Med Liver Dis, 2013, 23 (3) :183-187. (in Chinese) 唐礼瑞, 郭涛, 陶艳艳, 等.扶正化瘀胶囊联合核苷 (酸) 类药物治疗慢性乙型肝炎肝纤维化的初步系统评价[J].中西医结合肝病杂志, 2013, 23 (3) :183-187.
|
|
[16]ZHAO CQ, XU LM. Progress of clinical studies on Fuzheng Huyu capsule/tablet in treating liver fibrosis and liver cirrhosis[J]. World Chin Med, 2014, 9 (5) :561-567. (in Chinese) 赵长青, 徐列明.扶正化瘀胶囊/片治疗肝纤维化和肝硬化的临床研究进展[J].世界中医药, 2014, 9 (5) :561-567.
|
|
[17]CHEN Y, YANG YP. The role of traditional Chinese medicine in blocking and reversing hepatic fibrosis:Current status, hope, and challenge[J]. J Clin Hepatol, 2018, 34 (4) :689-693. (in Chinese) 陈艳, 杨永平.中医药阻断逆转肝纤维化的现状、希望与挑战[J].临床肝胆病杂志, 2018, 34 (4) :689-693.
|
|
[18]HUANG ZJ, ZENG CP. The therapy of entecavir combined with Anluo Huaxian capsule on HBe Ag positive chronic hepatitis B-related liver fibrosis in 134 cases[J]. Chin J Integr Tradit West Med Liver Dis, 2016, 26 (2) :74-75. (in Chinese) 黄志杰, 曾翠萍.恩替卡韦联合安络化纤丸治疗HBe Ag阳性慢性乙型肝炎肝纤维化134例[J].中西医结合肝病杂志, 2016, 26 (2) :74-75.
|
|
[19]CHEN HB. Clinical effect of entecavir combined with Dahuang Zhechong pills in the treatment of hepatitis B liver fibrosis[J].Clin Res Pract, 2018, 3 (5) :133-134. (in Chinese) 陈宏斌.恩替卡韦联合大黄蛰虫丸治疗乙型肝炎肝纤维化的临床效果[J].临床医学研究与实践, 2018, 3 (5) :133-134.
|
|
[20]WANG H, ZHAO YL, XU KC, et al. Clinical and pathological study on effects of Qianggan capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B[J]. Chin J Integr Trad West Med, 2006, 26 (11) :978-980. (in Chinese) 王华, 赵延龙, 徐克成, 等.强肝胶囊联合拉米夫定治疗慢性乙型肝炎肝纤维化的临床病理观察[J].中国中西医结合杂志, 2006, 26 (11) :978-980.
|
|
[21]LUO GA, WANG YM, CAO J, et al. Studies on establishment of modern quality standards system of traditional Chinese medicine in China[J]. World Sci Technol Modern Tradit Chin Med, 2002, 4 (4) :5-11, 79. (in Chinese) 罗国安, 王义明, 曹进, 等.建立我国现代中药质量标准体系的研究[J].世界科学技术-中医药现代化, 2002, 4 (4) :5-11, 79.
|
|
[22]LI B, PIAO JH. Study on the quality control of bioactivity in traditional Chinese medicine[J]. Drug Stand China, 2012, 13 (1) :5-8. (in Chinese) 李波, 朴晋华.中药生物活性质量控制的思考[J].中国药品标准, 2012, 13 (1) :5-8.
|
|
[23]LAM W, REN Y, GUAN F, et al. Mechanism based quality control (MBQC) of herbal products:A case study YIV-906 (PHY906) [J]. Front Pharmacol, 2018, 9:1324.
|
|
[24]SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65 (5) :1438-1450.
|
|
[25]XU S, WANG Y, TAI DCS, et al. qFibrosis:A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J]. J Hepatol, 2014, 61 (2) :260-269.
|
|
[26]GUO J, DONG Y, TANG JY. Discussion on clinical problems about bases of new drug oftraditional Chinese medicine development[J]. China J Chin Mater Med, 2017, 42 (5) :844-847. (in Chinese) 郭洁, 董宇, 唐健元.中药复方新药立题依据的临床问题探讨[J].中国中药杂志, 2017, 42 (5) :844-847.
|
|
[27]Writing Group of Principles of Dialectics of Nature. Principles of dialectics of nature[M]. Shanghai:Shanghai Scientific&Technical Publishers, 1985:202-214. (in Chinese) 《自然辩证法原理》编写组.自然辩证法原理[M].上海:上海科技出版社, 1985:202-214.
|
|
[28]ZHAO W, ZHAO ZM, WANG ZT, et al. Compare the effects of traditional Chinese prescriptions formulae for promoting blood circulation on liver fibrosis induced by DMN in rats[J]. Pharmocol Clin Chin Mater Med, 2012, 28 (3) :15-18. (in Chinese) 赵韦, 赵志敏, 王峥涛, 等.活血化瘀类方抗肝纤维化疗效比较[J].中药药理与临床, 2012, 28 (3) :15-18.
|
|
[29]GUO T, LIU ZL, ZHAO Q, et al. A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo[J]. Acta Pharmacol Sin, 2018, 39 (9) :1483-1492.
|
DownLoad: